The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.

Taste masking plays a vital role in treatment compliance according to Cargill, which has launched a new flavour technology that it claims can make drugs more pleasant to take and help manufacturers save money.

High potency APIs are becoming a key focus of the pharmaceutical business, with drug makers from all areas racing to establish a foothold in the market.

Contract services providers which embed service personnel in pharma companies are becoming more prominent in the industry.

Endeavour Specialty Chemicals has launched a novel range of pyridinyl thioureas designed to cater for growing pharmaceutical industry interest in the development of prion disease treatments.

Almac says growing demand for non-GMP manufacturing work rather than competition was the key driver for expansion of its product development services business.

Asking the right questions is key to giving pharmaceutical industry contract managers the information they need to select the best CRO partners according to the team behind a new performance assessment project.

BASF says solubility and bioavailability will be key focus for its pharmaceutical excipient product development efforts in the next few years.

CMO Aenova says demand for contract manufacturing capacity in Europe is increasing.

The human tissue supply industry is under pressure from CROs demanding more complex samples, according to equity analyst Vadim Alexandre.